Borderline resectable pancreatic cancer. challenges and controversies

Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in developed countries with an overall 5-year survival rate of 7% [1], and is expected to be the second cancer cause of death by 2030 [2]. Surgery still remains the best therapy for potentially curative purposes, but only 15-20% of the patients are candidates for resection. The resectability criteria are based on the absence of distant metastasis and the extent of vascular involvement. For a long time, tumours with no contact with major mesenteric or celiac vessels were considered resectable, and those with invasion of the arteries or mesenteric-portal axis were deemed unresectable.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research